KR950703947A - 고형 의약용 조성물의 제조방법(method of manufacturing composition for solid medicine) - Google Patents

고형 의약용 조성물의 제조방법(method of manufacturing composition for solid medicine)

Info

Publication number
KR950703947A
KR950703947A KR1019950701802A KR19950701802A KR950703947A KR 950703947 A KR950703947 A KR 950703947A KR 1019950701802 A KR1019950701802 A KR 1019950701802A KR 19950701802 A KR19950701802 A KR 19950701802A KR 950703947 A KR950703947 A KR 950703947A
Authority
KR
South Korea
Prior art keywords
potassium channel
channel activator
pharmaceutical composition
solid pharmaceutical
solvent
Prior art date
Application number
KR1019950701802A
Other languages
English (en)
Inventor
기요시 다무라
겐이찌 스기모리
겐지 오가와
Original Assignee
미즈노 시게루
니혼타 바꼬산교 가부시끼가이샤
원본미기재
요시또미세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미즈노 시게루, 니혼타 바꼬산교 가부시끼가이샤, 원본미기재, 요시또미세이야꾸 가부시끼가이샤 filed Critical 미즈노 시게루
Publication of KR950703947A publication Critical patent/KR950703947A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 의약 용액을 수득하기 위하여 용매에 칼륨 채널 활성화제를 용해시키고, 이 용매에 불활성이며 소정의 용출 속도를 얻기 위해 필요 충분한 양인 수불용성 셀룰로스의 거대 분자 물질에 의약용액을 첨가한 후, 이들을 함께 균일하게 혼합하고, 이어서 생성된 혼합물을 건조시켜서 이로부터 용매를 제거함을 특징으로 하는 조절된 용출 속도를 가지며 활성 성분으로 칼륨 채널 활성화제 및 약학적으로 허용 가능한 수불용성 셀룰로스의 거대 분자 물질을 함유하는 고형 의약용 조성물의 제조 방법； 및 이 제조 방법에 의하여 수득한 고형의 약 조성물에 관한 것이다. 본 발명의 방법에 의하여, 지속적 방출 의약인, 칼륨 채널 활성화제를 함유하는 의약의 활성 성분의 용출 속도가, 높은 재생산성으로 쉽게 조절될 수 있다.

Description

고형 의약용 조성물의 제조방법(METHOD OF MANUFACTURING COMPOSITION FOR SOLID MEDICINE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실험예1에서 수행한 용출 시험 결과를 보여주며;
제2도는 실험예2에서 수행한 용출 시험 결과를 보여주고; 및
제3도는 실험예3에서 수행한 용출 시험 결과를 보여준다.

Claims (4)

  1. 활성 성분으로 칼륨 채널 활성화제 및 약학적으로 허용 가능한 수불용성 셀룰로스 중합체를 함유하는 고형 의약용 조성물의 제조에 있어서, 칼륨 채널 활성화제를 용매에 용해시켜 의약 용액을 수득하고, 이 의약 용액을, 소정의 용출 속도 달성에 필요 충분한 양으로, 상기 용매에 불활성인 수불용성 셀룰로스 중합체에 첨가하고, 이를 균일하게 혼합하고, 이 혼합물을 건조시켜 용매를 제거함을 특징으로 하는 고형 의약용 조성물의 제조 방법.
  2. 제1항에 있어서, 칼륨 채널 활성화제가 크로만(chromane)유도체인 방법.
  3. 제1항 또는 제2항에 있어서, 약학적으로 허용 가능한 수불용성 셀룰로스 중합체가 결정성 셀룰로스, 카르복시메틸 셀룰로스, 카르복시메틸 셀룰로스-칼슘 또는 이의 혼합물인 방법.
  4. 제1항 내지 제3항 중 어느 한 항의 제조 방법에 의하여 수득 가능한 고형 의약용 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950701802A 1992-11-06 1993-11-05 고형 의약용 조성물의 제조방법(method of manufacturing composition for solid medicine) KR950703947A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP32142792 1992-11-06
JP92-321427 1992-11-06
PCT/JP1993/001603 WO1994010998A1 (en) 1992-11-06 1993-11-05 Method of manufacturing composition for solid medicine

Publications (1)

Publication Number Publication Date
KR950703947A true KR950703947A (ko) 1995-11-17

Family

ID=18132432

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701802A KR950703947A (ko) 1992-11-06 1993-11-05 고형 의약용 조성물의 제조방법(method of manufacturing composition for solid medicine)

Country Status (5)

Country Link
US (1) US5637322A (ko)
EP (1) EP0667153A4 (ko)
KR (1) KR950703947A (ko)
CA (1) CA2148220A1 (ko)
WO (1) WO1994010998A1 (ko)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5547615A (en) * 1978-09-29 1980-04-04 Taiyo Yakuhin Kogyo Kk Stable solid drug of nifedipine
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
KR940000232B1 (ko) * 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
JP2680602B2 (ja) * 1987-04-24 1997-11-19 第一製薬株式会社 徐放性錠剤
JPH01319416A (ja) * 1988-06-21 1989-12-25 Dai Ichi Kogyo Seiyaku Co Ltd 放出制御可能な錠剤結合剤
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
ZA918999B (en) * 1990-12-05 1992-08-26 Squibb & Sons Inc Method of treating shock using a potassium channel activator
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives

Also Published As

Publication number Publication date
US5637322A (en) 1997-06-10
CA2148220A1 (en) 1994-05-26
EP0667153A1 (en) 1995-08-16
EP0667153A4 (en) 1996-03-13
WO1994010998A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
CA1338889C (en) Morphine containing composition
DE3382587D1 (de) Injizierbares langwirkendes mikroteilchen-praeparat zur verabreichung entzuendungshemmender mittel.
KR930701983A (ko) 방출억제성 베라파밀 정제
DE69429820T2 (de) Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
IE781341L (en) Freeze drying
ATE77547T1 (de) Pharmazeutische zusammensetzungen mit verlaengerter wirkung und verfahren zu ihrer herstellung.
DE68923157T2 (de) Arzneimittel auf Trägern mit erhöhter Lösungsgeschwindigkeit und Verfahren zu ihrer Herstellung.
KR860006984A (ko) 서방성 제제의 제조방법
KR960013373A (ko) 물을 결합시킬수 있는 부형제를 포함하는 고형 약학 조성물
RU99104404A (ru) Фармацевтическая композиция из множества субъединиц и способ ее получения
CA2304662A1 (en) Methods for fabricating polymer-based controlled release preparations
BR0012972A (pt) Modos para criar uma massa tendo integridade estrutural
US4150110A (en) Coated granules of polyacrylic alkali metal salts and method of producing same
KR880004806A (ko) 분무 건조 아세트아미노펜
ATE216262T1 (de) Biologisch abbaubare polymermischungen zur arzneistoffabgabe
DK0394050T3 (da) Fremgangsmåde til fremstilling af en frysetørret formulering, som indeholder et lægemiddel
KR880004803A (ko) 분무 건조된 아세트아미노펜
DE3767998D1 (de) Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
ATE16394T1 (de) Stabile salze von s-adenosinylmethionin, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen welche als aktive substanz diese derivate enthalten.
MX9300265A (es) Composicion activa farmaceuticamente compuesta de tanacetum parthenium y derivados partenoliticos de sesquiterpen-lactona y procedimiento para su preparacion.
EP0195605A3 (en) Process of making gelled cellulose triacetate product and a product made thereby
KR840004347A (ko) 불안정한 약물 또는 음식물 첨가물의 안정화
KR950703947A (ko) 고형 의약용 조성물의 제조방법(method of manufacturing composition for solid medicine)
KR100321617B1 (ko) 항진균제와 유기산류의 공융혼합물 및 이를 함유하는 약학적 제제
ES8102803A1 (es) Procedimiento para la preparacion de cuerpos microporosos que engloben uno o mas agentes activos

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid